Clearside Biomedical presents new data from CLS-AX ODYSSEY phase 2b trial
February 11th 2025The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib injectable suspension) in participants with neovascular age-related macular degeneration.
Read More
4DMT announces positive 52-week data from phase 2b cohort of PRISM wet AMD study
February 10th 2025PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.
Read More
Study finds faricimab effective for nAMD patients unresponsive to other anti-VEGF treatments
February 6th 2025This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after 6 months of treatment in a retrospective chart review that included 102 patients with nAMD who had had suboptimal responses to other anti-VEGF therapies.
Read More
Mark Humayun, MD, PhD, discusses advance stem cell-derived therapies for dry AMD
December 16th 2024Researchers at the USC Ginsburg Institute for Biomedical Therapeutics and the USC Roski Eye Institute are advancing a new treatment for dry age-related macular degeneration, a leading cause of blindness in older adults.
Watch